NZ518164A - Rivastigmine for the treatment of ocular disorders - Google Patents

Rivastigmine for the treatment of ocular disorders

Info

Publication number
NZ518164A
NZ518164A NZ518164A NZ51816400A NZ518164A NZ 518164 A NZ518164 A NZ 518164A NZ 518164 A NZ518164 A NZ 518164A NZ 51816400 A NZ51816400 A NZ 51816400A NZ 518164 A NZ518164 A NZ 518164A
Authority
NZ
New Zealand
Prior art keywords
rivastigmine
ethyl
compound
hydrogen
formula
Prior art date
Application number
NZ518164A
Other languages
English (en)
Inventor
David Goldblum
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ518164A publication Critical patent/NZ518164A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ518164A 1999-10-19 2000-10-17 Rivastigmine for the treatment of ocular disorders NZ518164A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99120678 1999-10-19
PCT/EP2000/010234 WO2001028553A1 (en) 1999-10-19 2000-10-17 Rivastigmine for the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
NZ518164A true NZ518164A (en) 2003-10-31

Family

ID=8239225

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ518164A NZ518164A (en) 1999-10-19 2000-10-17 Rivastigmine for the treatment of ocular disorders

Country Status (13)

Country Link
US (2) US6534541B1 (enExample)
EP (1) EP1225890B1 (enExample)
JP (1) JP2003512324A (enExample)
AR (1) AR026062A1 (enExample)
AT (1) ATE285764T1 (enExample)
AU (1) AU766001B2 (enExample)
CA (1) CA2384690C (enExample)
DE (1) DE60017174T2 (enExample)
DK (1) DK1225890T3 (enExample)
ES (1) ES2234708T3 (enExample)
NZ (1) NZ518164A (enExample)
PT (1) PT1225890E (enExample)
WO (1) WO2001028553A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237163T3 (es) 1998-10-01 2005-07-16 Novartis Ag Nuevas formulaciones orales de revastigmina de liberacion controlada.
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
WO2009022345A1 (en) * 2007-08-14 2009-02-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Phenyl carbamates for the treatment of multiple sclerosis
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
CN107417574B (zh) * 2017-03-21 2019-12-03 浙江省医学科学院 2,4-双取代苯乙酮化合物及其旋光异构体、药学上可接受的盐及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
US4900748A (en) 1988-03-04 1990-02-13 The United States Of America As Represented By The Department Of Health And Human Services Carbamates related to (-)-physostigmine as cholinergic agents
JP3708957B2 (ja) 1991-09-26 2005-10-19 アメリカ合衆国 （−）−エゼロリン、（−）−ｎ１−ノルエゼロリンおよび（−）−ｎ１−ベンジルノルエゼロリンの置換フェンゼリンおよびフェニルカルバミン酸塩：特異的アセチルコリンエステラーゼ阻害薬としての使用
ES2206449T3 (es) 1991-09-26 2004-05-16 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services Inhibidores de colinesterasas, composiciones farmaceuticas y sus usos.
AU1138097A (en) * 1995-12-22 1997-07-17 Alcon Laboratories, Inc. Combinations of prostaglandins and miotics for lowering intraocular pressure

Also Published As

Publication number Publication date
ES2234708T3 (es) 2005-07-01
US6835748B2 (en) 2004-12-28
PT1225890E (pt) 2005-05-31
JP2003512324A (ja) 2003-04-02
AR026062A1 (es) 2002-12-26
EP1225890B1 (en) 2004-12-29
DK1225890T3 (da) 2005-04-04
WO2001028553A1 (en) 2001-04-26
DE60017174T2 (de) 2005-12-22
US20030119832A1 (en) 2003-06-26
US6534541B1 (en) 2003-03-18
AU2834901A (en) 2001-04-30
CA2384690C (en) 2010-08-17
DE60017174D1 (de) 2005-02-03
ATE285764T1 (de) 2005-01-15
EP1225890A1 (en) 2002-07-31
AU766001B2 (en) 2003-10-09
CA2384690A1 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
CA1208560A (en) Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5863948A (en) Increasing aqueous humor outflow
WO1989010757A1 (en) New ophthalmic preparation for treating glaucoma
US9694010B2 (en) Therapeutic formulation and methods of treatment
DE60132494T2 (de) Kupferchelatbildner zur behandlung von augenentzündungen
CA2384690C (en) Rivastigmine for the treatment of ocular disorders
KR20010040457A (ko) 안약 조성물
JPWO1993024121A1 (ja) 緑内障治療剤
US5196449A (en) Methods and pharmaceutical compositions for the treatment of ophthalmic diseases
SK79893A3 (en) Pharmaceutical agent in form of solution for local administration into eye for treatment of enhanced inside eyes pressure
RU2434633C2 (ru) Фармацевтические препаративные формы латрункулина
KR19980063712A (ko) 망막증의 치료에 유용한 저급 알카노일 ｌ-카르니틴
Goldblum et al. Topical rivastigmine, a selective acetylcholinesterase inhibitor, lowers intraocular pressure in rabbits
CA2187361A1 (en) Pharmaceutical composition for treating glaucoma containing terazosin
CN111450044A (zh) 一种含有灯盏乙素的眼用制剂、制备方法及其应用
US4477460A (en) Topical treatment of ocular hypertension
WO1995008990A1 (en) Increasing aqueous humor outflow

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed